Indegene to acquire BioPharm for up to USD 106 million

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

INDGN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹559.40

prior close

₹563.65

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.1%+0.4% vs market

Healthcare Services peers, median of 51sector · industry level+0.0%+1.5% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Smallcap 250 and 1.5 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.6

15m

+0.2

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+1.1+0.4+0.0+1.5

Next day

+3.6+1.9+1.6+0.6+2.9

+2.0+2.0-0.0+2.3-0.2

-1.3+2.1-3.4+1.7-3.0

-2.0+1.6-3.6+0.9-2.9

-1.5+1.9-3.4+0.8-2.3

-2.1+2.2-4.3+1.0-3.1

15d

-3.1+3.2-6.3+1.6-4.8

-4.2+4.4-8.6+2.9-7.0

-5.6+0.5-6.0-1.6-4.0

-7.0-0.1-6.8-3.9-3.0

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Services peers, median of 51Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indegene's wholly owned Ireland subsidiary will acquire 100% of US-based BioPharm Parent Holding and its subsidiaries for up to USD 106 million in cash, subject to working capital adjustments. The deal includes deferred, milestone-based payments and is expected to close on October 1, 2025. BioPharm provides data-driven marketing to life sciences clients, has over 90 US employees and reported 2024 revenue of USD 38.13 million.

Likely market impact

Broadens Indegene's life sciences marketing reach in North America but adds cash outlay and integration risk. Returns will depend on execution.